NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Thanks Flipper - I knew there was a trial measuring that but I didn't find it.

So far I've found (including the one you just gave me:

Newly Diagnosed

Clinical Trial: NCT03452579
Newly Diagnosed GBM
Nivo Plus Bevacizumab vs. Nivo Plus low dose Bevacizumab
P2
Note Primary Endpoint:
Survival at 12 months - in newly diagnosed GBM?
https://clinicaltrials.gov/ct2/show/study/NCT03452579#contacts

and….

Clinical Trial: NCT02667587
Checkmate 548
TMZ Plus Radiation w/Nivo or Placebo WITH MGMT methylated tumors
P3
Primary Endpoints:
Co - endpoints: PFS and OS
https://clinicaltrials.gov/ct2/show/NCT02667587?term=CheckMate+548&rank=1

and…

Clinical Trial: NCT02617589
Checkmate 498
Newly Diagnosed GBM
Nivo compared to TMZ - each given Radiation - MGMT-unmethylated
Primary: Measures OS at 3 years
Secondary: PFS at 24 months
https://clinicaltrials.gov/ct2/show/NCT02617589

and

Clinical Trial: NCT03367715
Newly Diagnosed GBM
Nivolumab, Ipilimumab, Short-course Radiotherapy (no TMZ), MGMT Unmethylated
P2
Primary Endpoint:
OS at one year
Secondary Endpoint:
OS at two years
https://clinicaltrials.gov/ct2/show/NCT03367715

Recurrent GBM

Clinical Trial: NCT03452579
Recurrent GBM
Nivolumab (Opdivo) with Low Dose Avasitin (Bevacizumab)
P2
Primary Endpoint:
Survival at 12 months
https://clinicaltrials.gov/ct2/show/study/NCT03452579#contacts

and…

Clinical Trial: NCT02017717
Recurrent GBM
Checkmate 143
Nivolumab w/Bevacizumab compared to Nivolumab alone and Nivo with Ipilimumab
P3
Two primary endpoints:
For Cohort One: measuring safety and tolerability
For Cohort Two: measuring Nivo compared to Bevacizumab
Active, not recruiting
https://clinicaltrials.gov/ct2/show/NCT02017717

and…

Clinical Trial: NCT03743662
Recurrent GBM
Nivolumab with Radiation Therapy and Bevacizumab - MGMT Methylated
P2
Arms include those who have surgery after recurrence and those who don’t
https://clinicaltrials.gov/ct2/show/NCT03743662